Theravance Biopharma Reports Q2 2025 Results with 83.2% Revenue Growth, Exceeding Analyst Expectations

Theravance Biopharma reported Q2 2025 revenue of $26.2 million, an 83.2% YoY increase, exceeding analyst expectations. Net income reached $54.8 million due to a one-time $75.1 million gain from the TRELEGY royalty asset sale. YUPELRI collaboration revenue rose 31% YoY, driven by strong US commercialization efforts, but underlying demand grew only 4% YoY. The company's focus on expanding YUPELRI and advancing ampreloxetine through pivotal clinical trials is crucial for future growth.

Theravance Biopharma Inc. (TBPH) reported robust financial results for the second quarter of 2025, significantly outperforming analyst expectations. The company's earnings per share (EPS) came in at $1.08, well above the forecasted $0.67, marking a 61.19% surprise. Revenue also beat estimates, reaching $26.2 million compared to the projected $15.92 million, a 64.57% surprise. Following the announcement, Theravance’s stock rose by 4.56% in after-hours trading, reflecting investor optimism [1].

The company’s revenue growth was driven by strong sales of its key product, YUPELRI, which saw a 22% year-over-year increase. The company’s strategic focus on expanding its market share and optimizing its product offerings has paid off, as evidenced by its financial results. The completion of the $225 million sale of its Trelegy royalty interest also contributed to a healthy cash position, allowing the company to maintain operations with minimal cash burn [1].

YUPELRI collaboration revenue rose 31% YoY, driven by strong US commercialization efforts, but underlying demand grew only 4% YoY. The company's focus on expanding YUPELRI and advancing ampreloxetine through pivotal clinical trials is crucial for future growth [1].

Theravance Biopharma ended the quarter with $340 million in cash and no debt, maintaining a healthy current ratio of 4.77, indicating robust liquidity. The company’s strong financial position and strategic direction were highlighted by CEO Rick Winningham and Chief Business Officer Rhonda Farnam during the earnings call [1].

Looking ahead, Theravance Biopharma reaffirmed its financial guidance for 2025, anticipating improved non-GAAP losses and reduced cash burn in the second half of the year. The company is eagerly awaiting the top-line data from its Cypress Phase 3 study, expected in approximately six months. Additionally, potential milestone payments from Trelegy and YUPELRI could further bolster financial performance [1].

References:
[1] https://www.investing.com/news/transcripts/earnings-call-transcript-theravance-biopharma-q2-2025-earnings-beat-expectations-93CH-4186884